Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma
Condition: Lymphoma
MeSH terms: Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin
Intervention: asparaginase; cyclophosphamide; cytarabine; daunorubicin hydrochloride; dexamethasone; doxorubicin hydrochloride; leucovorin calcium; mercaptopurine; methotrexate; prednisone; thioguanine; vincristine sulfate; radiation therapy
Intervention description: Given IV; Given IV; Given IV; Given IV; Given IV; Given IV; Given IV; Given IV; Given IV; Given IV; Given PO; Given IV
Intervention MeSH terms: Leucovorin; Cytarabine; Dexamethasone; Prednisone; Cyclophosphamide; Doxorubicin; Liposomal doxorubicin; Methotrexate; Vincristine; Daunorubicin; Asparaginase; Mercaptopurine; Thioguanine; Levoleucovorin
Phase: Phase 3
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Enrollment: 393.0
Sex: All
Minimum age: 1 Year
Maximum age: 30 Years
Healthy volunteers: No
Keywords: stage III childhood lymphoblastic lymphoma; stage IV childhood lymphoblastic lymphoma

Summary:

      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
      so they stop growing or die. It is not yet known which regimen of combination chemotherapy is
      most effective for lymphoblastic lymphoma.

      PURPOSE: This randomized phase III trial is studying different regimens of combination
      chemotherapy to compare how well they work in treating children or adolescents with newly
      diagnosed stage III or stage IV lymphoblastic lymphoma.
    

Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Newly diagnosed disseminated lymphoblastic lymphoma or localized lymphoblastic
             lymphoma*

               -  Less than 25% tumor cells in the bone marrow

               -  Previously untreated (prior intrathecal cytarabine allowed if protocol therapy
                  begins within 72 hours)

               -  Stage III or IV disease

          -  NOTE: *Localized lymphoblastic lymphoma is closed to accrual as of 10/2005

        PATIENT CHARACTERISTICS:

        Age:

          -  1 to 30

        Performance status:

          -  Not specified

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Not specified

        Renal:

          -  Not specified

        Cardiovascular:

          -  Adequate cardiac function

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  See Disease Characteristics

        Endocrine therapy:

          -  Emergency steroid therapy (if required) must be started within 72 hours prior to
             protocol therapy

        Radiotherapy:

          -  Emergency radiotherapy (if required) must be started within 72 hours prior to protocol
             therapy

        Surgery:

          -  Not specified

        Other:

          -  No other prior therapy except for emergency treatment of airway obstruction and/or
             superior vena cava syndrome